Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine

Joel E. Gallant, Richard D Moore, Douglas D. Richman, Jeanne C Keruly, Richard E Chaisson

Research output: Contribution to journalArticle

Abstract

Background: Although the cause of Kaposi's sarcoma (KS) is unknown, its unique epidemiology suggests that an infectious, sexually transmitted agent or agents may contribute to its pathogenesis. Methods: To assess the natural history of KS associated with the acquired immunodeficiency syndrome and to identify factors associated with its development, data were analyzed from a multicenter, observational cohort study of 1044 persons with the acquired immunodeficiency syndrome or the acquired immunodeficiency syndrome-related complex and a total CD4 cell count of less than 0.25x109/L who were treated with zidovudine between April 1987 and April 1988. Records were reviewed bimonthly. Follow-up continued for 2 years or until death. Results: One hundred thirty-one patients (13%) had KS at study enrollment, and 143 developed KS (14%) during follow-up, with a 2-year actuarial risk of 21%. The probability of KS at 2 years for patients with initial CD4 cell counts of less than 0.1x109/L was 25%, compared with 15% for those with counts of 0.1x109/L or more. By logistic regression, a baseline CD4 cell count of less than 0.1x109/L (relative odds, 1.43; 95% confidence interval, 1.04 to 1.95), homosexuality (relative odds, 3.71; 95% confidence interval, 1.82 to 7.56), cytomegalovirus disease (relative odds, 1.56; 95% confidence interval, 1.01 to 2.41), and white race (relative odds, 1.64; 95% confidence interval, 1.11 to 2.43) were independently associated with KS. Median survival after KS was 408 days, and KS was an independent predictor of death (relative hazard, 1.78; 95% confidence interval, 1.26 to 2.52). Conclusions: Kaposi's sarcoma contributes to human immunodeficiency virus-related morbidity and mortality, especially among male homosexuals. This large cohort study provides further evidence for an association between risk for cytomegalovirus infection and KS.

Original languageEnglish (US)
Pages (from-to)566-572
Number of pages7
JournalArchives of Internal Medicine
Volume154
Issue number5
DOIs
StatePublished - Mar 14 1994

Fingerprint

Zidovudine
Kaposi's Sarcoma
Virus Diseases
HIV
Confidence Intervals
CD4 Lymphocyte Count
Odds Ratio
Acquired Immunodeficiency Syndrome
Cohort Studies
Homosexuality
Cytomegalovirus Infections
Cytomegalovirus
Observational Studies
Epidemiology
Logistic Models
Morbidity
Survival
Mortality

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. / Gallant, Joel E.; Moore, Richard D; Richman, Douglas D.; Keruly, Jeanne C; Chaisson, Richard E.

In: Archives of Internal Medicine, Vol. 154, No. 5, 14.03.1994, p. 566-572.

Research output: Contribution to journalArticle

@article{75d242d6ed414240b5d7601df76db3ca,
title = "Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine",
abstract = "Background: Although the cause of Kaposi's sarcoma (KS) is unknown, its unique epidemiology suggests that an infectious, sexually transmitted agent or agents may contribute to its pathogenesis. Methods: To assess the natural history of KS associated with the acquired immunodeficiency syndrome and to identify factors associated with its development, data were analyzed from a multicenter, observational cohort study of 1044 persons with the acquired immunodeficiency syndrome or the acquired immunodeficiency syndrome-related complex and a total CD4 cell count of less than 0.25x109/L who were treated with zidovudine between April 1987 and April 1988. Records were reviewed bimonthly. Follow-up continued for 2 years or until death. Results: One hundred thirty-one patients (13{\%}) had KS at study enrollment, and 143 developed KS (14{\%}) during follow-up, with a 2-year actuarial risk of 21{\%}. The probability of KS at 2 years for patients with initial CD4 cell counts of less than 0.1x109/L was 25{\%}, compared with 15{\%} for those with counts of 0.1x109/L or more. By logistic regression, a baseline CD4 cell count of less than 0.1x109/L (relative odds, 1.43; 95{\%} confidence interval, 1.04 to 1.95), homosexuality (relative odds, 3.71; 95{\%} confidence interval, 1.82 to 7.56), cytomegalovirus disease (relative odds, 1.56; 95{\%} confidence interval, 1.01 to 2.41), and white race (relative odds, 1.64; 95{\%} confidence interval, 1.11 to 2.43) were independently associated with KS. Median survival after KS was 408 days, and KS was an independent predictor of death (relative hazard, 1.78; 95{\%} confidence interval, 1.26 to 2.52). Conclusions: Kaposi's sarcoma contributes to human immunodeficiency virus-related morbidity and mortality, especially among male homosexuals. This large cohort study provides further evidence for an association between risk for cytomegalovirus infection and KS.",
author = "Gallant, {Joel E.} and Moore, {Richard D} and Richman, {Douglas D.} and Keruly, {Jeanne C} and Chaisson, {Richard E}",
year = "1994",
month = "3",
day = "14",
doi = "10.1001/archinte.154.5.566",
language = "English (US)",
volume = "154",
pages = "566--572",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine

AU - Gallant, Joel E.

AU - Moore, Richard D

AU - Richman, Douglas D.

AU - Keruly, Jeanne C

AU - Chaisson, Richard E

PY - 1994/3/14

Y1 - 1994/3/14

N2 - Background: Although the cause of Kaposi's sarcoma (KS) is unknown, its unique epidemiology suggests that an infectious, sexually transmitted agent or agents may contribute to its pathogenesis. Methods: To assess the natural history of KS associated with the acquired immunodeficiency syndrome and to identify factors associated with its development, data were analyzed from a multicenter, observational cohort study of 1044 persons with the acquired immunodeficiency syndrome or the acquired immunodeficiency syndrome-related complex and a total CD4 cell count of less than 0.25x109/L who were treated with zidovudine between April 1987 and April 1988. Records were reviewed bimonthly. Follow-up continued for 2 years or until death. Results: One hundred thirty-one patients (13%) had KS at study enrollment, and 143 developed KS (14%) during follow-up, with a 2-year actuarial risk of 21%. The probability of KS at 2 years for patients with initial CD4 cell counts of less than 0.1x109/L was 25%, compared with 15% for those with counts of 0.1x109/L or more. By logistic regression, a baseline CD4 cell count of less than 0.1x109/L (relative odds, 1.43; 95% confidence interval, 1.04 to 1.95), homosexuality (relative odds, 3.71; 95% confidence interval, 1.82 to 7.56), cytomegalovirus disease (relative odds, 1.56; 95% confidence interval, 1.01 to 2.41), and white race (relative odds, 1.64; 95% confidence interval, 1.11 to 2.43) were independently associated with KS. Median survival after KS was 408 days, and KS was an independent predictor of death (relative hazard, 1.78; 95% confidence interval, 1.26 to 2.52). Conclusions: Kaposi's sarcoma contributes to human immunodeficiency virus-related morbidity and mortality, especially among male homosexuals. This large cohort study provides further evidence for an association between risk for cytomegalovirus infection and KS.

AB - Background: Although the cause of Kaposi's sarcoma (KS) is unknown, its unique epidemiology suggests that an infectious, sexually transmitted agent or agents may contribute to its pathogenesis. Methods: To assess the natural history of KS associated with the acquired immunodeficiency syndrome and to identify factors associated with its development, data were analyzed from a multicenter, observational cohort study of 1044 persons with the acquired immunodeficiency syndrome or the acquired immunodeficiency syndrome-related complex and a total CD4 cell count of less than 0.25x109/L who were treated with zidovudine between April 1987 and April 1988. Records were reviewed bimonthly. Follow-up continued for 2 years or until death. Results: One hundred thirty-one patients (13%) had KS at study enrollment, and 143 developed KS (14%) during follow-up, with a 2-year actuarial risk of 21%. The probability of KS at 2 years for patients with initial CD4 cell counts of less than 0.1x109/L was 25%, compared with 15% for those with counts of 0.1x109/L or more. By logistic regression, a baseline CD4 cell count of less than 0.1x109/L (relative odds, 1.43; 95% confidence interval, 1.04 to 1.95), homosexuality (relative odds, 3.71; 95% confidence interval, 1.82 to 7.56), cytomegalovirus disease (relative odds, 1.56; 95% confidence interval, 1.01 to 2.41), and white race (relative odds, 1.64; 95% confidence interval, 1.11 to 2.43) were independently associated with KS. Median survival after KS was 408 days, and KS was an independent predictor of death (relative hazard, 1.78; 95% confidence interval, 1.26 to 2.52). Conclusions: Kaposi's sarcoma contributes to human immunodeficiency virus-related morbidity and mortality, especially among male homosexuals. This large cohort study provides further evidence for an association between risk for cytomegalovirus infection and KS.

UR - http://www.scopus.com/inward/record.url?scp=0028219411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028219411&partnerID=8YFLogxK

U2 - 10.1001/archinte.154.5.566

DO - 10.1001/archinte.154.5.566

M3 - Article

C2 - 8122950

AN - SCOPUS:0028219411

VL - 154

SP - 566

EP - 572

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 5

ER -